Navigation Links
PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Date:5/30/2012

SPRINGFIELD, Ore., May 30, 2012 /PRNewswire/ -- PeaceHealth Laboratories today announced the national availability and receipt of a federal patent for PtProtect™ (Patient Protect), a pain medication monitoring program offering the industry's highest levels of accuracy to detect prescription pain medication and identify potential negative drug interactions before they occur. PtProtect directly addresses the safety and financial concerns of prescription pain medication abuse by using the most sensitive and definitive assays to detect medication and illicit drugs.

In the most recent review period January – April, 2012, PeaceHealth Laboratories found that 35 percent of PtProtect test results returned discrepant results outside a patient's known prescriptions. Because PtProtect identifies patients who are taking or potentially diverting prescribed pain medications, taking pain medications that are not prescribed to them, or using drugs of abuse it has the potential to significantly reduce accidental deaths. (1)

"PtProtect saves lives, saves practices and saves communities money," said Ran Whitehead, Chief Executive Officer of PeaceHealth Laboratories. "Now physicians may know, with confidence, what pain medications their patient is taking and prescribe accordingly to the highest levels of safety. This patent validates our rigorous science and practical application of this life-saving technology. It also enables providers to protect their practices from uncertain liabilities including malpractice and patient mortality."

In recognition of PtProtect's technology and capabilities, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,067,243 granting exclusive rights to PtProtect™.  

About PtProtect

PtProtect is a patented testing program that detects up to 38 prescribed medications and illicit drugs. Medications are revealed at the industry's lowest thresholds for the most sensitive, comprehensive detection of opiates and opioids, thus reducing the possibility of adverse drug interactions. Simple and timely reporting allows doctors to quickly determine if test results are consistent or inconsistent with patient prescriptions.

PtProtect is available through PeaceHealth Laboratories and may be administered by physicians nationwide. For information about PtProtect, visit www.ptprotect.com or call 800-826-3616.

About PeaceHealth Laboratories

PeaceHealth Laboratories is a division of PeaceHealth, a not-for-profit health care system with a mission of promoting personal and community health since 1890. PeaceHealth Laboratories provides comprehensive laboratory services throughout the Pacific Northwest (Oregon, Washington and Alaska), and specialty testing for clinicians and employers across the U.S. With 9 laboratories and 27 patient service centers in three states, PeaceHealth Laboratories is one of the largest laboratory systems in the Pacific Northwest. Learn more at www.peacehealthlabs.org

(1) Source: CNNMoney February 24, 2012


'/>"/>
SOURCE PeaceHealth Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PeaceHealth Standardizes Hematology Operations With Sysmex
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Romark Laboratories Raises $18 Million in Institutional Financing
6. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):